45 summarised stories about Scientific Discovery, each linking back to the original source. Browse all topics →
The New York Times 1 month ago 38 ● 3 sources
Rentosertib, an AI-assisted drug candidate, showed early evidence that it may slow aging beyond treating chronic lung disease. It reduced biological-age markers across six aging clocks. The results mean the drug’s potential is expanding to aging, though it is still years away from regulatory approval.
Nature Publishing Group US 1 month ago 8 ● 3 sources
Insilico’s AI-designed TNIK inhibitor rentosertib (INS018_055) was evaluated in a phase 2a IPF trial using serum proteomics analyzed by six proteomic aging clocks. At 12 weeks, 21 of 54 treatment-vs-placebo clock comparisons were statistically significant, with most occurring at week 4. All six clocks showed reduced predicted biological age in treated groups versus minimal change in placebo, shifting trial readouts toward measurable aging-rate deceleration alongside disease effects.
The daily briefing
TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.
TLDRocket
15 October 2026
OpenAI’s DevDay set the tone for how AI products are tightening around cost, computation, and agents—while legal pressure keeps reminding everyone that capability doesn’t ship in a vacuum. The headline was GPT-6.1 Sol and its Dots autonomous agent, positioned for higher tool-call volume and longer internal runs. Pricing is blunt: $2 per million input tokens and $10 per million output tokens, pitched as roughly one-fifth the per-task cost of GPT-6 Astra. The catch is availability and scope—Dots is rolling out only to specific ChatGPT plans, while the overall direction is clear: more work moved from chat into orchestration, where agents do the scheduling, retrieval, and stepwise execution.
Read the full briefing →